All news

Edwards Lifesciences gains 16.6% as guidance and trial data lift sentiment

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Edwards Lifesciences shares are up 16.6% over the past month and 18.2% year-to-date after positive third-quarter results, a raised full-year sales guidance and fresh clinical trial data. The stock trades near its average analyst target of

Read original source

EW company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.